Stock Scorecard

Stock Summary for Zenas Biopharma Inc (ZBIO) - $16.32 as of 7/25/2025 1:26:25 PM EST

Total Score

3 out of 30

Safety Score

2 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZBIO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ZBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ZBIO (2 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for ZBIO

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 6/20/2025 8:15:00 PM
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Zenas BioPharma ( NASDAQ:ZBIO ) 6/16/2025 5:25:00 PM
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Zenas BioPharma, Inc. ( ZBIO ) 6/15/2025 12:05:00 PM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO - Zenas BioPharma ( NASDAQ:ZBIO ) 6/13/2025 5:23:00 PM
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Zenas BioPharma ( NASDAQ:ZBIO ) 6/12/2025 10:17:00 PM
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd Announces that Zenas BioPharma, Inc. ( ZBIO ) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Zenas BioPharma ( NASDAQ:ZBIO ) 6/11/2025 6:30:00 PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm - Ibotta ( NYSE:IBTA ) , Avis Budget Gr ( NASDAQ:CAR ) 6/10/2025 1:00:00 AM
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO - Zenas BioPharma ( NASDAQ:ZBIO ) 6/9/2025 5:34:00 PM
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of June 16, 2025 Lead Plaintiff Deadline in the Zenas BioPharma, Inc. ( ZBIO ) Securities Class Action - Investors With Significant Losses Encouraged to Contact the Firm - Zenas BioPharma ( NASDAQ:ZBIO ) 6/9/2025 12:30:00 PM
ZBIO FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - ZBIO - Zenas BioPharma ( NASDAQ:ZBIO ) 6/8/2025 10:30:00 PM

Financial Details for ZBIO

Company Overview
Ticker ZBIO
Company Name Zenas Biopharma Inc
Country N/A
Description N/A
Sector Name N/A
Industry Name N/A
Most Recent Quarter N/A
Next Earnings Date N/A

Stock Price History
Last Day Price 16.32
Price 4 Years Ago 0.00
Last Day Price Updated 7/25/2025 1:26:25 PM EST
Last Day Volume 222,565
Average Daily Volume 202,598
52-Week High 0.00
52-Week Low 0.00
Last Price to 52 Week Low 0.00%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE 0.00
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 0.00
Total Cash Per Share 0.00
Book Value Per Share Most Recent Quarter 0.00
Price to Book Ratio 0.00
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 0
Market Capitalization 0
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 0.00%
Reported EPS 12 Trailing Months 0.00
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.00
Net Income Twelve Trailing Months 0
Net Income Past Year 0
Net Income Prior Year 0
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 0
Total Cash Past Year 0
Total Cash Prior Year 0
Net Cash Position Most Recent Quarter 0
Net Cash Position Past Year 0
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 0
Total Stockholder Equity Prior Year 0
Total Stockholder Equity Most Recent Quarter 0

Free Cash Flow
Free Cash Flow Twelve Trailing Months 0
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year 0
Free Cash Flow Prior Year 0

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 1.04
MACD Signal 0.64
20-Day Bollinger Lower Band 6.23
20-Day Bollinger Middle Band 10.13
20-Day Bollinger Upper Band 14.02
Beta 0.00
RSI 68.88
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System
Modified 9/21/2024 5:37:18 PM EST